<p>蘭頓製藥公司（納斯達克股票代碼：LTRN - 獲取免費報告）在六月份的短期利空大幅下降。截至 6 月 15 日，短期利空股票總數為 333,500 股，較 5 月 31 日的 419,800 股下降了 20.6%。根據平均每日交易量為 163,200 股，目前的短期利空比率為 2.0 天。公司股票中約有 4.2% 被做空。</p>
<p>獲取 <strong>蘭頓製藥</strong> 警報：</p>
<h2>內部買賣</h2>
<ul>
<li>8 家股價低於 10 美元的最佳人工智能股票</li>
</ul>
<p>相關新聞中，主要股東 Aaron G.L. Fletcher 於 5 月 23 日星期四以每股 6.25 美元的平均價格出售了蘭頓製藥公司的 10,000 股股票，總交易額為 62,500.00 美元。交易完成後，該內部人士現持有公司股票的 59,326 股，價值約為 370,787.50 美元。該交易已在證券交易委員會的法律文件中披露，可通過此鏈接查看。目前公司股票的 6.92% 由內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一家機構投資者最近增加了其在蘭頓製藥公司股票中的持倉。根據最新提交給證券交易委員會的 13F 文件，Meridian Wealth Management LLC 在第四季度將其在蘭頓製藥公司（納斯達克股票代碼：LTRN - 免費報告）的持股增加了 18.0%，在此期間購入了額外的 3,000 股。Meridian Wealth Management LLC 在最新提交給證券交易委員會的文件中擁有公司股票 19,660 股，價值 84,000 美元。機構投資者和對沖基金共持有公司股票的 28.62%。</p>
<h2>分析師設定新的價格目標</h2>
<p>另外，HC Wainwright 在 4 月 25 日的報告中重申了對蘭頓製藥的 “中性” 評級。</p>
<p>獲取我們對蘭頓製藥的最新股票分析</p>
<h2>蘭頓製藥股價表現</h2>
<p>LTRN 股票週五開盤價為 4.67 美元。該公司的市值為 5025 萬美元，市盈率為-2.87，貝塔係數為 1.61。蘭頓製藥的一年最低價為 2.38 美元，最高價為 11.99 美元。該公司的五十日移動平均價為 5.64 美元，兩百日移動平均價為 5.52 美元。</p>
<p>蘭頓製藥（納斯達克股票代碼：LTRN - 獲取免費報告）最近公佈了截至 5 月 9 日的季度財報。公司報告的每股虧損為（0.51）美元，低於市場預期的（0.43）美元。賣方分析師平均預計，蘭頓製藥今年將實現每股-2.23 美元的虧損。</p>
<h2>蘭頓製藥公司簡介（獲取免費報告）</h2>
<p>蘭頓製藥公司是一家臨牀階段的生物技術公司，專注於人工智能、機器學習和基因組數據，以簡化藥物開發流程。其產品管線包括 LP-300，正在進行第 2 期臨牀試驗，用於非吸煙者非小細胞肺腺癌的聯合治療；LP-184，正在進行第 1 期臨牀試驗，用於胰腺、乳腺、膀胱和肺癌、膠質母細胞瘤和其他中樞神經系統癌症的治療；以及 LP-284，正在進行第 1 期臨牀試驗，用於非霍奇金淋巴瘤的治療，包括曼特爾細胞淋巴瘤和雙擊淋巴瘤。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比蘭頓製藥更好</li>
<li>高股息房地產投資信託：它們是多樣化的理想方式嗎？</li>
<li>瓦爾格林斯股價暴跌背後的原因：投資者下一步該怎麼做</li>
<li>尋找並有利可圖地交易 52 周最低股票</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
<li>想要從下降趨勢中獲利？下降趨勢，解釋。</li>
<li>通用磨坊股價在 2024 財年第四季度營收不及預期後下跌</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 拜登接班的幾率提高了 105%！（來自自由港協會）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4"/></p>
<h2>您現在是否應該投資 1,000 美元購買蘭頓製藥？</h2>
<p>在考慮蘭頓製藥之前，您可能想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們建議客户購買的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而蘭頓製藥不在名單上。</p>
<p>雖然蘭頓製藥目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

摯文集團

<p>摯文集團（NASDAQ:LTRN）在六月份經歷了空頭頭寸的顯著下降，與五月相比，空頭頭寸下降了 20.6%。該公司的股票目前有 4.2% 被做空，空頭頭寸比率為 2.0 天。此外，一位主要股東出售了 1 萬股摯文集團的股票。機構投資者和對沖基金擁有該公司 28.62% 的股份。分析師們給予摯文集團中立評級。該公司專注於利用人工智能和基因組數據進行藥物開發</p>

<p>Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 333,500 shares, a decline of 20.6% from the May 31st total of 419,800 shares. Based on an average daily trading volume, of 163,200 shares, the short-interest ratio is currently 2.0 days. Approximately 4.2% of the company's stock are short sold.</p>
<div class="lb-trans"><p>蘭頓製藥公司（納斯達克股票代碼：LTRN - 獲取免費報告）在六月份的短期利空大幅下降。截至 6 月 15 日，短期利空股票總數為 333,500 股，較 5 月 31 日的 419,800 股下降了 20.6%。根據平均每日交易量為 163,200 股，目前的短期利空比率為 2.0 天。公司股票中約有 4.2% 被做空。</p>
</div><p>Get <strong>Lantern Pharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>蘭頓製藥</strong> 警報：</p>
</div><h2>Insider Buying and Selling</h2>
<ul>
<li>8 Best Artificial Intelligence Stocks Under $10</li>
</ul>
<div class="lb-trans"><h2>內部買賣</h2>
<ul>
<li>8 家股價低於 10 美元的最佳人工智能股票</li>
</ul>
</div><p>In related news, major shareholder Aaron G.L. Fletcher sold 10,000 shares of Lantern Pharma stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $6.25, for a total transaction of $62,500.00. Following the sale, the insider now owns 59,326 shares of the company's stock, valued at approximately $370,787.50. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. 6.92% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>相關新聞中，主要股東 Aaron G.L. Fletcher 於 5 月 23 日星期四以每股 6.25 美元的平均價格出售了蘭頓製藥公司的 10,000 股股票，總交易額為 62,500.00 美元。交易完成後，該內部人士現持有公司股票的 59,326 股，價值約為 370,787.50 美元。該交易已在證券交易委員會的法律文件中披露，可通過此鏈接查看。目前公司股票的 6.92% 由內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>An institutional investor recently raised its position in Lantern Pharma stock. Meridian Wealth Management LLC increased its holdings in Lantern Pharma Inc. (NASDAQ:LTRN - Free Report) by 18.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 19,660 shares of the company's stock after buying an additional 3,000 shares during the period. Meridian Wealth Management LLC owned about 0.18% of Lantern Pharma worth $84,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 28.62% of the company's stock.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了其在蘭頓製藥公司股票中的持倉。根據最新提交給證券交易委員會的 13F 文件，Meridian Wealth Management LLC 在第四季度將其在蘭頓製藥公司（納斯達克股票代碼：LTRN - 免費報告）的持股增加了 18.0%，在此期間購入了額外的 3,000 股。Meridian Wealth Management LLC 在最新提交給證券交易委員會的文件中擁有公司股票 19,660 股，價值 84,000 美元。機構投資者和對沖基金共持有公司股票的 28.62%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>Separately, HC Wainwright reissued a &#34;neutral&#34; rating on shares of Lantern Pharma in a report on Thursday, April 25th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 4 月 25 日的報告中重申了對蘭頓製藥的 “中性” 評級。</p>
</div><p><strong>Get Our Latest Stock Analysis on Lantern Pharma</strong></p>
<div class="lb-trans"><p>獲取我們對蘭頓製藥的最新股票分析</p>
</div><h2>Lantern Pharma Price Performance</h2>
<div class="lb-trans"><h2>蘭頓製藥股價表現</h2>
</div><p>Shares of LTRN stock opened at $4.67 on Friday. The firm has a market cap of $50.25 million, a P/E ratio of -2.87 and a beta of 1.61. Lantern Pharma has a 1-year low of $2.38 and a 1-year high of $11.99. The firm has a fifty day moving average of $5.64 and a two-hundred day moving average of $5.52.</p>
<div class="lb-trans"><p>LTRN 股票週五開盤價為 4.67 美元。該公司的市值為 5025 萬美元，市盈率為-2.87，貝塔係數為 1.61。蘭頓製藥的一年最低價為 2.38 美元，最高價為 11.99 美元。該公司的五十日移動平均價為 5.64 美元，兩百日移動平均價為 5.52 美元。</p>
</div><p>Lantern Pharma (NASDAQ:LTRN - Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). On average, sell-side analysts expect that Lantern Pharma will post -2.23 EPS for the current year.</p>
<div class="lb-trans"><p>蘭頓製藥（納斯達克股票代碼：LTRN - 獲取免費報告）最近公佈了截至 5 月 9 日的季度財報。公司報告的每股虧損為（0.51）美元，低於市場預期的（0.43）美元。賣方分析師平均預計，蘭頓製藥今年將實現每股-2.23 美元的虧損。</p>
</div><h2>Lantern Pharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>蘭頓製藥公司簡介（獲取免費報告）</h2>
</div><p>Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.</p>
<div class="lb-trans"><p>蘭頓製藥公司是一家臨牀階段的生物技術公司，專注於人工智能、機器學習和基因組數據，以簡化藥物開發流程。其產品管線包括 LP-300，正在進行第 2 期臨牀試驗，用於非吸煙者非小細胞肺腺癌的聯合治療；LP-184，正在進行第 1 期臨牀試驗，用於胰腺、乳腺、膀胱和肺癌、膠質母細胞瘤和其他中樞神經系統癌症的治療；以及 LP-284，正在進行第 1 期臨牀試驗，用於非霍奇金淋巴瘤的治療，包括曼特爾細胞淋巴瘤和雙擊淋巴瘤。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Lantern Pharma</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比蘭頓製藥更好</li>
<li>高股息房地產投資信託：它們是多樣化的理想方式嗎？</li>
<li>瓦爾格林斯股價暴跌背後的原因：投資者下一步該怎麼做</li>
<li>尋找並有利可圖地交易 52 周最低股票</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
<li>想要從下降趨勢中獲利？下降趨勢，解釋。</li>
<li>通用磨坊股價在 2024 財年第四季度營收不及預期後下跌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前已經由 MarketBeat 的編輯團隊進行了審查。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Odds of Biden Replacement Up 105%! (From The Freeport Society)(Ad)</p>
<div class="lb-trans"><p>→ 拜登接班的幾率提高了 105%！（來自自由港協會）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8588&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Lantern Pharma right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買蘭頓製藥？</h2>
</div><p>Before you consider Lantern Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮蘭頓製藥之前，您可能想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantern Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師以及他們建議客户購買的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而蘭頓製藥不在名單上。</p>
</div><p>While Lantern Pharma currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然蘭頓製藥目前在分析師中有一個 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Lantern Pharma Inc.（納斯達克股票代碼：LTRN）的空頭頭寸顯著下降